Share this story:

Ventripoint Announces CEO to Give Medical Keynote Presentation at Wall Street Conference in January and Engagement of Lyons Capital LLC





Toronto, Ontario / TheNewswire / December 13, 2018 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company") (TSXV:VPT, OTCQB:VPTDF) announces that it has entered into a contract with Lyons Capital LLC. ("Lyons") for a Platinum Sponsorship and a Medical Keynote presentation slot at the 2019 Wall Street Conference on January 16, 2019 at Mar-a-Lago, Florida, and for introductions within the investment community to increase market exposure, in compliance with regulatory guidelines.

"We are very pleased to have Ventripoint presenting as the Medical Device keynote speaker at this year's conference," stated Jason Lyons, Founder and CEO of Lyons Capital, the organizer of the Wall Street Conference.

Started in 2000 and based in Boca Raton, Florida, Lyons Capital LLC is owned by Jason Lyons, CEO. Lyons Capital's primary businesses include venture capital investments and organizing the annual Wall Street Conference, the premier conference in the venture capital and small cap marketplace. Attendees range from members of the investment banking community and private equity funds to sophisticated investors.

Under the terms of the contract Lyons has been retained for 6 months, beginning December 1, 2018. The Company previously announced (NR November 14, 2018) that the contract fee of US$150,000 would be paid in common shares. The payment terms have been re-negotiated so that the fee is now payable in cash at the end of the contract term.

About Ventripoint Diagnostics Ltd.

Ventripoint's technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR), used to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Company has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.

For further information, contact:

Dr. George Adams, CEO

T: (519) 803-6937

E: gadams@ventripoint.com

Forward Looking Statements:

This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. The use of any of the words "expect", "anticipate", "continue", "estimate", "objective", "ongoing", "may", "will", "project", "should", "believe", "plans", "intends" and similar expressions are intended to identify forward-looking information or statements. The forward-looking statements and information are based on certain key expectations and assumptions made by the Corporation. Although the Corporation believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Corporation can give no assurance that they will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. Other factors, which could materially affect such forward-looking information are described in the risk factors in the Corporation's most recent annual management's discussion and analysis that is available on the Corporation's profile on SEDAR at www.sedar.com. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements included in this news release are expressly qualified by this cautionary statement. The forward-looking statements and information contained in this news release are made as of the date hereof and the Corporation undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.